CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

References

• HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer20099857658619629072
   PubMed Web of Science ®Google Scholar
• DestaZWardBASoukhovaNVFlockhartDAComprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6J Pharmacol Exp Ther200431031062107515159443
   PubMed Web of Science ®Google Scholar
• LimYCLiLDestaZEndoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cellsJ Pharmacol Exp Ther2006318250351216690721
   PubMed Web of Science ®Google Scholar
• FabianCTilzerLSternsonLComparative binding affinities of tamoxifen, 4-hydroxytamoxifen,and desmethyltamoxifen for estrogen receptor isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancerBiopharma Drug Dispos198124381390
   Web of Science ®Google Scholar
• JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• HigginsMJStearnsVUnderstanding resistance to tamoxifen in hormone receptor-positive breast cancerClin Chem20095581453145519541862
   PubMed Web of Science ®Google Scholar
• GoetzMPRaeJMSumanVJPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesJ Clin Oncol200523369312931816361630
   PubMed Web of Science ®Google Scholar
• KnoxSKIngleJNSumanVJCytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam)J Clin Oncol20062418S504
   Google Scholar
• StearnsVJohnsonMDRaeJMActive tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineJ Natl Cancer Inst200395231758156414652237
   PubMed Web of Science ®Google Scholar
• LimH-SJu LeeHSeok LeeKSook LeeEJangIJRoJClinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancerJ Clin Oncol200725253837384517761971
   PubMed Web of Science ®Google Scholar
• BorgesSDestaZLiLQuantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentClin Pharmacol Ther2006801617416815318
   PubMed Web of Science ®Google Scholar
• LimJSLChenXASinghOImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBr J Clin Pharmacol201171573775021480951
   PubMed Web of Science ®Google Scholar
• NowellSAhnJRaeJAssociation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Res Treat200591324925815952058
   PubMed Web of Science ®Google Scholar
• GoetzMPSchaidDJWickerhamDLEvaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsClin Cancer Res201117216944695121880792
   PubMed Web of Science ®Google Scholar
• SchrothWAntoniadouLFritzPBreast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesJ Clin Oncol200725335187519318024866
   PubMed Web of Science ®Google Scholar
• SchrothWGoetzMPHamannUAssociation between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenJAMA2009302131429143619809024
   PubMed Web of Science ®Google Scholar
• SchrothWHamannUFaschingPACYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratificationClin Cancer Res201016174468447720515869
   PubMed Web of Science ®Google Scholar
• KiyotaniKMushirodaTSasaMImpact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapyCancer Sci200899599599918294285
   PubMed Web of Science ®Google Scholar
• XuYSunYYaoLAssociation between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnn Oncol20081981423142918407954
   PubMed Web of Science ®Google Scholar
• ToyamaTYamashitaHSugiuraHKondoNIwaseHFujiiYNo association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatmentJpn J Clin Oncol2009391065165619596663
   PubMed Web of Science ®Google Scholar
• PechatananKJaruhathaiSAtivitavasTCytochrome P450 2D6 polymorphisms of Thai breast cancer patients and their outcomes of adjuvant tamoxifenJ Clin Oncol.2007Suppl Abstr e11037
   Google Scholar
• BonanniBMacisDMaisonneuvePPolymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flash: data from the Italian Tamoxifen TrialJ Clin Oncol200624223708370916877740
   PubMed Web of Science ®Google Scholar
• TheLKMohamedNISallehMZThe risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1AAPS J2012141525922183189
   PubMed Web of Science ®Google Scholar
• FleemanNMartin SaboridoCPayneKThe clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic reviewHealth Technol Assess201115331102
   Web of Science ®Google Scholar
• RamamoorthyYTyndaleRFSellersEMCytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substratesPharmacogenetics200111647748711505218
   PubMedGoogle Scholar